| abstract |
As used herein, selected from one or more muscarinic receptor antagonists (“MRAs”) and one or more β2-agonists, p38 MAP kinase inhibitors, PDE-IV inhibitors, corticosteroids or mixtures thereof Pharmaceutical compositions are provided comprising at least one additional active ingredient and optionally one or more pharmaceutically acceptable carriers, excipients or diluents. In addition, methods for treating autoimmunity, inflammation or allergic diseases or disorders are provided. [Selection figure] None |